Executive Team

Restorative Therapies through Innate Integrity

Amniox Medical, Inc.

Executive Team

Barry Hassett
Vice President of Marketing
Barry Hassett joined Amniox Medical in April 2013 as Vice President of Marketing with more than 20 years of experience in a variety of medical device and biologic sectors including orthopedics, oncology, renal care and vascular surgery.  Barry has led marketing teams and creative initiatives for several start-up companies that successfully launched disruptive technologies.  Prior to Amniox, he served as Vice President of Marketing for Carticept Medical
®, CardioMEMS® (acquired by St. Jude®) and DaVita Healthcare®. His first start-up venture was as Director of Marketing for Proxima Therapeutics, Inc.®, a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors.   Proxima was acquired by Cytyc Corporation® in March 2005 for $190 million. Prior to that he held positions of increasing responsibility in clinical research, regulatory affairs and marketing in the orthopedic industry.  He holds a Bachelor of Science in Bioengineering from Duke University and a Masters of Science in Bioengineering from Dartmouth College.

Lita Lilly
Vice President of Sales
Lita Lilly joined Amniox Medical in 2015 as Vice President of Sales.  Lita started her medical career serving in the US Army Nurse Corp.  She has over 25 years in the medical sales,  launching her sales career with J&J
® in pharmaceutical sales and then transitioning on to medical devices with Smith & Nephew® Wound Management Division where she started as an Account Manager then progressed into sales management  where she spent 15 years developing high performing sales teams. She is a graduate of the Emory University Wound, Ostomy, and Continence Educational Center. Lita holds a Bachelor of Science in Nursing from East Carolina University and is an active Licensed RN. 

Scheffer C.G. Tseng, MD, PhD.
Chief Scientific Officer

Dr. Tseng is a physician scientist and serves as the Chief Scientific Officer of TissueTech, Inc., the leading U.S. tissue engineering company in Ophthalmology. Dr. Tseng specializes in ocular surface disease and reconstruction through epithelial stem cell and amniotic membrane transplantation. His research focuses on the novel amniotic membrane matrix, and has been continuously supported by the NIH and National Eye Institute for over 25 years. He has produced more than 280 papers in the field of ocular surface disease and reconstruction, has trained more than 80 international fellows specialized in ocular surface diseases, and served as the first President of International Ocular Surface Society. Dr. Tseng received his M.D. from National Taiwan University Medical School (1978), and PhD from University of California San Francisco (1981). He completed the ophthalmology residency at Johns Hopkins Hospital (1984) and the cornea and external disease fellowship at Massachusetts Eye & Ear Infirmary, Harvard Medical School (1986).

Dr. Tseng serves as an ad hoc member on several NIH study sections and the editorial board for the Ocular Surface Journal and Cornea Journal. He is an ARVO fellow and the medical director of Ocular Surface Center and Ocular Surface Research & Education Foundation.

 

Amniox Medical

  • 888-709-2140